Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to Hold by StockNews.com

StockNews.com upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a sell rating to a hold rating in a research report report published on Thursday morning.

Separately, HC Wainwright reaffirmed a neutral rating on shares of Aclaris Therapeutics in a research note on Monday, July 22nd. Seven analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of Hold and an average target price of $22.25.

Aclaris Therapeutics Stock Performance

ACRS opened at $1.39 on Thursday. Aclaris Therapeutics has a fifty-two week low of $0.59 and a fifty-two week high of $10.15. The company has a market capitalization of $99.06 million, a P/E ratio of -1.28 and a beta of 0.27. The stock has a fifty day moving average of $1.18 and a 200-day moving average of $1.20.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. Aclaris Therapeutics had a negative return on equity of 61.03% and a negative net margin of 248.28%. The company had revenue of $2.40 million during the quarter, compared to the consensus estimate of $1.99 million. On average, equities research analysts predict that Aclaris Therapeutics will post -0.77 earnings per share for the current fiscal year.

Insider Activity at Aclaris Therapeutics

In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard bought 130,317 shares of the stock in a transaction on Thursday, July 18th. The stock was purchased at an average price of $1.30 per share, with a total value of $169,412.10. Following the completion of the purchase, the insider now owns 13,578,286 shares in the company, valued at $17,651,771.80. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders purchased a total of 2,435,393 shares of company stock valued at $2,750,797 over the last quarter. 6.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ACRS. SG Americas Securities LLC grew its holdings in shares of Aclaris Therapeutics by 69.5% during the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 13,461 shares during the last quarter. Vontobel Holding Ltd. grew its holdings in shares of Aclaris Therapeutics by 128.8% during the fourth quarter. Vontobel Holding Ltd. now owns 30,268 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 17,040 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Aclaris Therapeutics by 115.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,784 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 23,467 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Aclaris Therapeutics by 10.9% during the first quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock worth $299,000 after purchasing an additional 23,747 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Aclaris Therapeutics during the first quarter worth about $39,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.